Presentación de PowerPointdm2renality.es/cong3/files/pdf/gil2-dia1.pdf · Median age: 57.3 7 male,...
Transcript of Presentación de PowerPointdm2renality.es/cong3/files/pdf/gil2-dia1.pdf · Median age: 57.3 7 male,...
![Page 1: Presentación de PowerPointdm2renality.es/cong3/files/pdf/gil2-dia1.pdf · Median age: 57.3 7 male, 9 female All stage IV disease 22 lesions irradiated, 16 lung 4 bone & 2 1-NS 1](https://reader034.fdocumento.com/reader034/viewer/2022042321/5f0b148a7e708231d42ec056/html5/thumbnails/1.jpg)
Dr. Ignacio Gil-Bazo
Enfermedad Oligometastásica
![Page 2: Presentación de PowerPointdm2renality.es/cong3/files/pdf/gil2-dia1.pdf · Median age: 57.3 7 male, 9 female All stage IV disease 22 lesions irradiated, 16 lung 4 bone & 2 1-NS 1](https://reader034.fdocumento.com/reader034/viewer/2022042321/5f0b148a7e708231d42ec056/html5/thumbnails/2.jpg)
Pembrolizumab tras tratamiento local ablativo
O. Primario• PFS• Seguridad
O. Secund.• OS• QoL
![Page 3: Presentación de PowerPointdm2renality.es/cong3/files/pdf/gil2-dia1.pdf · Median age: 57.3 7 male, 9 female All stage IV disease 22 lesions irradiated, 16 lung 4 bone & 2 1-NS 1](https://reader034.fdocumento.com/reader034/viewer/2022042321/5f0b148a7e708231d42ec056/html5/thumbnails/3.jpg)
Pembrolizumab tras tratamiento local ablativo
![Page 4: Presentación de PowerPointdm2renality.es/cong3/files/pdf/gil2-dia1.pdf · Median age: 57.3 7 male, 9 female All stage IV disease 22 lesions irradiated, 16 lung 4 bone & 2 1-NS 1](https://reader034.fdocumento.com/reader034/viewer/2022042321/5f0b148a7e708231d42ec056/html5/thumbnails/4.jpg)
ATOM: Tratamiento ablativo tras 1L EGFR TKI
![Page 5: Presentación de PowerPointdm2renality.es/cong3/files/pdf/gil2-dia1.pdf · Median age: 57.3 7 male, 9 female All stage IV disease 22 lesions irradiated, 16 lung 4 bone & 2 1-NS 1](https://reader034.fdocumento.com/reader034/viewer/2022042321/5f0b148a7e708231d42ec056/html5/thumbnails/5.jpg)
ATOM: Tratamiento ablativo tras 1L EGFR TKI
![Page 6: Presentación de PowerPointdm2renality.es/cong3/files/pdf/gil2-dia1.pdf · Median age: 57.3 7 male, 9 female All stage IV disease 22 lesions irradiated, 16 lung 4 bone & 2 1-NS 1](https://reader034.fdocumento.com/reader034/viewer/2022042321/5f0b148a7e708231d42ec056/html5/thumbnails/6.jpg)
ATOM: Tratamiento ablativo tras 1L EGFR TKI
![Page 7: Presentación de PowerPointdm2renality.es/cong3/files/pdf/gil2-dia1.pdf · Median age: 57.3 7 male, 9 female All stage IV disease 22 lesions irradiated, 16 lung 4 bone & 2 1-NS 1](https://reader034.fdocumento.com/reader034/viewer/2022042321/5f0b148a7e708231d42ec056/html5/thumbnails/7.jpg)
Tratamiento local más TKIs en CNMP oligom. EGFR+
![Page 8: Presentación de PowerPointdm2renality.es/cong3/files/pdf/gil2-dia1.pdf · Median age: 57.3 7 male, 9 female All stage IV disease 22 lesions irradiated, 16 lung 4 bone & 2 1-NS 1](https://reader034.fdocumento.com/reader034/viewer/2022042321/5f0b148a7e708231d42ec056/html5/thumbnails/8.jpg)
Tratamiento local más TKIs en CNMP oligom. EGFR+
![Page 9: Presentación de PowerPointdm2renality.es/cong3/files/pdf/gil2-dia1.pdf · Median age: 57.3 7 male, 9 female All stage IV disease 22 lesions irradiated, 16 lung 4 bone & 2 1-NS 1](https://reader034.fdocumento.com/reader034/viewer/2022042321/5f0b148a7e708231d42ec056/html5/thumbnails/9.jpg)
Tratamiento Local en oligometástasis sincrónicasen pacientes con tumores EGFR + tratados con TKIs
![Page 10: Presentación de PowerPointdm2renality.es/cong3/files/pdf/gil2-dia1.pdf · Median age: 57.3 7 male, 9 female All stage IV disease 22 lesions irradiated, 16 lung 4 bone & 2 1-NS 1](https://reader034.fdocumento.com/reader034/viewer/2022042321/5f0b148a7e708231d42ec056/html5/thumbnails/10.jpg)
Tratamiento Local en oligometástasis sincrónicasen pacientes con tumores EGFR + tratados con TKIs
![Page 11: Presentación de PowerPointdm2renality.es/cong3/files/pdf/gil2-dia1.pdf · Median age: 57.3 7 male, 9 female All stage IV disease 22 lesions irradiated, 16 lung 4 bone & 2 1-NS 1](https://reader034.fdocumento.com/reader034/viewer/2022042321/5f0b148a7e708231d42ec056/html5/thumbnails/11.jpg)
Tratamiento Local en oligometástasis sincrónicasen pacientes con tumores EGFR + tratados con TKIs
![Page 12: Presentación de PowerPointdm2renality.es/cong3/files/pdf/gil2-dia1.pdf · Median age: 57.3 7 male, 9 female All stage IV disease 22 lesions irradiated, 16 lung 4 bone & 2 1-NS 1](https://reader034.fdocumento.com/reader034/viewer/2022042321/5f0b148a7e708231d42ec056/html5/thumbnails/12.jpg)
Tratamiento Local en oligometástasis sincrónicasen pacientes con tumores EGFR + tratados con TKIs
![Page 13: Presentación de PowerPointdm2renality.es/cong3/files/pdf/gil2-dia1.pdf · Median age: 57.3 7 male, 9 female All stage IV disease 22 lesions irradiated, 16 lung 4 bone & 2 1-NS 1](https://reader034.fdocumento.com/reader034/viewer/2022042321/5f0b148a7e708231d42ec056/html5/thumbnails/13.jpg)
Actualización de PFS y OS a 6 años
![Page 14: Presentación de PowerPointdm2renality.es/cong3/files/pdf/gil2-dia1.pdf · Median age: 57.3 7 male, 9 female All stage IV disease 22 lesions irradiated, 16 lung 4 bone & 2 1-NS 1](https://reader034.fdocumento.com/reader034/viewer/2022042321/5f0b148a7e708231d42ec056/html5/thumbnails/14.jpg)
Actualización de PFS y OS a 6 años